HK1184451A1 - 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors 4--2--1--4- - Google Patents

4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors 4--2--1--4-

Info

Publication number
HK1184451A1
HK1184451A1 HK13111845.9A HK13111845A HK1184451A1 HK 1184451 A1 HK1184451 A1 HK 1184451A1 HK 13111845 A HK13111845 A HK 13111845A HK 1184451 A1 HK1184451 A1 HK 1184451A1
Authority
HK
Hong Kong
Prior art keywords
pyrrazole
aminoquinazolin
carboxylic acid
acid compounds
prolyl hydroxylase
Prior art date
Application number
HK13111845.9A
Other languages
English (en)
Chinese (zh)
Inventor
Michael H Rabinowitz
Mark D Rosen
Kyle T Tarantino
Hariharan Venkatesan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1184451A1 publication Critical patent/HK1184451A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK13111845.9A 2010-08-13 2013-10-22 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors 4--2--1--4- HK1184451A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37366410P 2010-08-13 2010-08-13
PCT/US2011/047626 WO2012021830A1 (en) 2010-08-13 2011-08-12 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
HK1184451A1 true HK1184451A1 (en) 2014-01-24

Family

ID=44533176

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13111845.9A HK1184451A1 (en) 2010-08-13 2013-10-22 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors 4--2--1--4-

Country Status (7)

Country Link
US (5) US8796263B2 (xx)
EP (1) EP2603502B1 (xx)
JP (1) JP5755741B2 (xx)
CN (1) CN103068821B (xx)
AU (1) AU2011289230B2 (xx)
HK (1) HK1184451A1 (xx)
WO (1) WO2012021830A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484678B1 (en) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
JP5755741B2 (ja) * 2010-08-13 2015-07-29 ヤンセン ファーマシューティカ エヌ．ベー． プロリルヒドロキシラーゼインヒビタとしての４−アミノキナゾリン−２−イル−１−ピラゾール−４−カルボン酸化合物
EP3461820B1 (en) 2011-10-25 2020-07-29 Janssen Pharmaceutica NV Method for obtaining crystals of meglumine salt of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
AU2015311333B2 (en) 2014-09-02 2017-11-16 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
CN109641886B (zh) * 2015-11-25 2022-11-18 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
TW202200134A (zh) 2020-04-20 2022-01-01 美商阿克比治療有限公司 治療病毒感染、器官損傷及相關症狀之方法
AU2021263829A1 (en) * 2020-04-29 2022-12-15 BioAge Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
WO2022033420A1 (zh) * 2020-08-14 2022-02-17 成都海博为药业有限公司 一种作为pak4激酶抑制剂的化合物及其制备方法和应用
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
WO2023064512A1 (en) * 2021-10-13 2023-04-20 Board Of Regents, The University Of Texas System Compositions and methods for modulating mitochondrial function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
WO2007070359A2 (en) 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
PE20071020A1 (es) 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
NZ601730A (en) 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
DE102006050513A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
ES2524883T3 (es) 2008-03-18 2014-12-15 Merck Sharp & Dohme Corp. 4-Hidroxipirimidina-5-carboxamidas sustituidas
DE112009001995A5 (de) * 2008-08-22 2011-09-29 Inventus Engineering Gmbh Bewegung dämpfende Vorrichtung
ES2548250T3 (es) 2009-02-10 2015-10-15 Janssen Pharmaceutica, N.V. Quinazolinonas como inhibidores de prolilhidroxilasa
JP5755741B2 (ja) * 2010-08-13 2015-07-29 ヤンセン ファーマシューティカ エヌ．ベー． プロリルヒドロキシラーゼインヒビタとしての４−アミノキナゾリン−２−イル−１−ピラゾール−４−カルボン酸化合物

Also Published As

Publication number Publication date
CN103068821A (zh) 2013-04-24
US10246442B2 (en) 2019-04-02
WO2012021830A1 (en) 2012-02-16
US9573940B2 (en) 2017-02-21
CN103068821B (zh) 2015-02-25
US20180148435A9 (en) 2018-05-31
US20140309215A1 (en) 2014-10-16
US20200095234A1 (en) 2020-03-26
US20150197507A1 (en) 2015-07-16
US20130143871A1 (en) 2013-06-06
US8796263B2 (en) 2014-08-05
US20170320859A1 (en) 2017-11-09
US10975062B2 (en) 2021-04-13
US9006251B2 (en) 2015-04-14
AU2011289230A1 (en) 2013-02-21
EP2603502B1 (en) 2014-07-30
EP2603502A1 (en) 2013-06-19
JP5755741B2 (ja) 2015-07-29
AU2011289230B2 (en) 2014-09-04
JP2013536194A (ja) 2013-09-19

Similar Documents

Publication Publication Date Title
HK1223104A1 (zh) 作為治療劑之精胺酸酶抑制劑
HK1206743A1 (en) 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors hif 4--
EP2563771A4 (en) METALLOENZYME INHIBITOR COMPOUNDS
ZA201401310B (en) Polymorphic forms of compounds as prolyl hydroxylase inhibitor,and uses thereof
HK1184451A1 (en) 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors 4--2--1--4-
HK1198163A1 (en) Metalloenzyme inhibitor compounds
HK1198651A1 (en) Metalloenzyme inhibitor compounds
EP2584903A4 (en) NEW HETEROCYCLIC COMPOUNDS AS ERK HEMMER
HK1205103A1 (en) Metalloenzyme inhibitor compounds
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
HK1190334A1 (en) Prolyl hydroxylase inhibitors
EP2528926A4 (en) HEPATITIS C INHIBITOR COMPOUNDS
EP2757884A4 (en) PYRAZOLOPYRIDYL COMPOUNDS AS AN ALDOSTERONE SYNTHESIS HEMMER
EP2723730A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
GB201004311D0 (en) New enzyme inhibitor compounds
EP2638021A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
EP2632903A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
EP2632268A4 (en) NEW CONNECTIONS AS ERK HEMMER
EP2651905A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
HK1191327A1 (en) Azaspirodecanone compounds as hsl inhibitors hsl
GB201002752D0 (en) Benzimidazol-2-ones as inhibitors for prolyl endopeptidase
SI2496236T1 (sl) Prolilhidroksilazni inhibitorji
GB201004308D0 (en) New inhibitor compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230810